IL36299A - 3-octadecyloxypropyl-2'-(trimethylammonium)ethyl phosphate,its preparation and pharmaceutical compositions containing it - Google Patents
3-octadecyloxypropyl-2'-(trimethylammonium)ethyl phosphate,its preparation and pharmaceutical compositions containing itInfo
- Publication number
- IL36299A IL36299A IL36299A IL3629971A IL36299A IL 36299 A IL36299 A IL 36299A IL 36299 A IL36299 A IL 36299A IL 3629971 A IL3629971 A IL 3629971A IL 36299 A IL36299 A IL 36299A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- octadecyloxypropyl
- prepared
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- -1 phosphoric acid-monobromoethyl ester dichloride ( 2-bromoethyl phosphorodichloridate) Chemical compound 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 4
- 229940035437 1,3-propanediol Drugs 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 3
- 229940071536 silver acetate Drugs 0.000 claims description 3
- HVWGGPRWKSHASF-UHFFFAOYSA-N Sulfuric acid, monooctadecyl ester Chemical compound CCCCCCCCCCCCCCCCCCOS(O)(=O)=O HVWGGPRWKSHASF-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000010617 anise oil Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ZNJOCVLVYVOUGB-UHFFFAOYSA-N 1-iodooctadecane Chemical compound CCCCCCCCCCCCCCCCCCI ZNJOCVLVYVOUGB-UHFFFAOYSA-N 0.000 description 1
- FRUYNPJKMKKZPE-UHFFFAOYSA-N 2-bromoethyl dihydrogen phosphate;dihydrochloride Chemical compound Cl.Cl.OP(O)(=O)OCCBr FRUYNPJKMKKZPE-UHFFFAOYSA-N 0.000 description 1
- ZNVBMQIWZIDDCS-UHFFFAOYSA-N 3-octadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOCCCO ZNVBMQIWZIDDCS-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000011720 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2009341A DE2009341C3 (de) | 1970-02-27 | 1970-02-27 | 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL36299A0 IL36299A0 (en) | 1971-04-28 |
| IL36299A true IL36299A (en) | 1974-12-31 |
Family
ID=5763597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL36299A IL36299A (en) | 1970-02-27 | 1971-02-26 | 3-octadecyloxypropyl-2'-(trimethylammonium)ethyl phosphate,its preparation and pharmaceutical compositions containing it |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US3708558A (ja) |
| JP (1) | JPS558995B1 (ja) |
| AT (1) | AT299248B (ja) |
| BE (1) | BE763578A (ja) |
| BG (1) | BG17619A3 (ja) |
| CH (1) | CH542247A (ja) |
| CS (1) | CS152390B2 (ja) |
| DE (1) | DE2009341C3 (ja) |
| DK (1) | DK129352B (ja) |
| ES (1) | ES388446A1 (ja) |
| FR (1) | FR2081545B1 (ja) |
| GB (1) | GB1280788A (ja) |
| HU (1) | HU162911B (ja) |
| IE (1) | IE34973B1 (ja) |
| IL (1) | IL36299A (ja) |
| NL (1) | NL168518C (ja) |
| NO (1) | NO134057C (ja) |
| PL (1) | PL74270B1 (ja) |
| RO (1) | RO58353A (ja) |
| SE (1) | SE369192B (ja) |
| YU (1) | YU35144B (ja) |
| ZA (1) | ZA711241B (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792662A (fr) * | 1971-12-13 | 1973-06-13 | Hoechst Ag | Composes du phosphore qui sont des ions mixtes |
| DE2345060C3 (de) * | 1973-09-06 | 1982-04-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | 1,2-Dialkylketonglycerin-3-phosphatide und Verfahren zu deren Herstellung |
| DE2619686C2 (de) * | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verwendung eines Lysolecithins zur Tumorbehandlung |
| GB2046092B (en) * | 1979-03-05 | 1983-11-02 | Toyama Chemical Co Ltd | Pharmaceutical composition containing a lysophospholid and a phospholipid |
| CA1138773A (en) * | 1979-04-18 | 1983-01-04 | George Wojcik | Synthetic adjuvants for stimulation of antigenic responses |
| US4551532A (en) * | 1980-05-08 | 1985-11-05 | Takeda Chemical Industries, Ltd. | Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity |
| US4504474A (en) * | 1980-06-27 | 1985-03-12 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
| US4329302A (en) * | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
| EP0050327B1 (de) * | 1980-10-21 | 1984-06-20 | Roche Diagnostics GmbH | Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP0061872B1 (en) * | 1981-03-30 | 1985-08-07 | Takeda Chemical Industries, Ltd. | Ethyleneglycol derivatives, their production and use |
| DE3127503A1 (de) * | 1981-07-11 | 1983-02-17 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| JPS60130429U (ja) * | 1984-02-09 | 1985-08-31 | スタンレー電気株式会社 | タツチスイツチ付液晶表示パネル |
| JPS60130428U (ja) * | 1984-02-09 | 1985-08-31 | スタンレー電気株式会社 | タツチスイツチ付液晶表示パネル |
| EP0299965A4 (en) * | 1986-03-24 | 1992-12-16 | University Of Sydney | Antigenic analogues of platelet activating factor (paf) |
| US4888328A (en) * | 1988-03-10 | 1989-12-19 | Hoeschst-Roussel Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| US5036152A (en) * | 1988-03-10 | 1991-07-30 | Hoechst-Roussel Pharmaceuticals Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| DE3906952A1 (de) * | 1989-03-04 | 1990-09-06 | Boehringer Mannheim Gmbh | (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel |
| WO2001039724A2 (en) | 1999-12-03 | 2001-06-07 | The Regents Of The University Of California, San Diego | Phosphonate compounds |
| JP2008535862A (ja) | 2005-04-08 | 2008-09-04 | キメリクス，インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
| EP3085377A1 (en) | 2008-01-25 | 2016-10-26 | Chimerix, Inc. | Methods of treating viral infections |
| US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| PT2534150T (pt) | 2010-02-12 | 2017-05-02 | Chimerix Inc | Métodos para tratar uma infecção viral |
| US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
-
1970
- 1970-02-27 DE DE2009341A patent/DE2009341C3/de not_active Expired
-
1971
- 1971-02-12 YU YU343/71A patent/YU35144B/xx unknown
- 1971-02-16 RO RO65949A patent/RO58353A/ro unknown
- 1971-02-16 BG BG016830A patent/BG17619A3/xx unknown
- 1971-02-18 CS CS1230A patent/CS152390B2/cs unknown
- 1971-02-19 ES ES388446A patent/ES388446A1/es not_active Expired
- 1971-02-23 US US00118083A patent/US3708558A/en not_active Expired - Lifetime
- 1971-02-24 CH CH279071A patent/CH542247A/de not_active IP Right Cessation
- 1971-02-25 NL NLAANVRAGE7102495,A patent/NL168518C/xx not_active IP Right Cessation
- 1971-02-25 JP JP962071A patent/JPS558995B1/ja active Pending
- 1971-02-26 SE SE02515/71A patent/SE369192B/xx unknown
- 1971-02-26 AT AT168571A patent/AT299248B/de not_active IP Right Cessation
- 1971-02-26 ZA ZA711241A patent/ZA711241B/xx unknown
- 1971-02-26 IL IL36299A patent/IL36299A/en unknown
- 1971-02-26 FR FR7106702A patent/FR2081545B1/fr not_active Expired
- 1971-02-26 PL PL1971146518A patent/PL74270B1/pl unknown
- 1971-02-26 HU HUTO845A patent/HU162911B/hu unknown
- 1971-02-26 NO NO727/71A patent/NO134057C/no unknown
- 1971-02-26 DK DK88571AA patent/DK129352B/da unknown
- 1971-02-26 BE BE763578A patent/BE763578A/xx unknown
- 1971-02-26 IE IE245/71A patent/IE34973B1/xx unknown
- 1971-04-19 GB GB22746/71A patent/GB1280788A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE763578A (fr) | 1971-08-26 |
| ES388446A1 (es) | 1973-05-01 |
| YU35144B (en) | 1980-09-25 |
| BG17619A3 (bg) | 1973-11-10 |
| NL168518C (nl) | 1982-04-16 |
| RO58353A (ja) | 1975-07-15 |
| ZA711241B (en) | 1971-12-29 |
| PL74270B1 (ja) | 1974-10-30 |
| DE2009341A1 (de) | 1971-09-02 |
| DE2009341B2 (de) | 1978-10-19 |
| US3708558A (en) | 1973-01-02 |
| HU162911B (ja) | 1973-04-28 |
| NL168518B (nl) | 1981-11-16 |
| JPS558995B1 (ja) | 1980-03-07 |
| NO134057B (ja) | 1976-05-03 |
| DK129352C (ja) | 1975-03-03 |
| GB1280788A (en) | 1972-07-05 |
| DE2009341C3 (de) | 1979-06-21 |
| FR2081545A1 (ja) | 1971-12-03 |
| IE34973B1 (en) | 1975-10-01 |
| IE34973L (en) | 1971-08-27 |
| YU34371A (en) | 1980-03-15 |
| DK129352B (da) | 1974-09-30 |
| NO134057C (ja) | 1976-08-11 |
| SE369192B (ja) | 1974-08-12 |
| CS152390B2 (ja) | 1973-12-19 |
| AT299248B (de) | 1972-06-12 |
| NL7102495A (ja) | 1971-08-31 |
| FR2081545B1 (ja) | 1974-03-22 |
| CH542247A (de) | 1973-09-30 |
| IL36299A0 (en) | 1971-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL36299A (en) | 3-octadecyloxypropyl-2'-(trimethylammonium)ethyl phosphate,its preparation and pharmaceutical compositions containing it | |
| US4119714A (en) | Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens | |
| CN104402753B (zh) | 一种金刚烷胺人工半抗原、人工抗原及其制备方法和应用 | |
| US3694473A (en) | Higher alkano yl-propanediol-(1,3)-2 -trimethylammonium-ethyl phosphates | |
| EP0647649B1 (en) | Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative | |
| US3752886A (en) | Lysolecithins as immunologic adjuvants | |
| Weiss et al. | Aromatic Biosynthesis. XV. 1 The Isolation and Identification of Shikimic Acid 5-Phosphate2a, 2b | |
| IE51038B1 (en) | Oxiranebutanoic acid derivatives,their preparation and use,and medicaments containing them | |
| US4218436A (en) | Compounds and methods | |
| CN108047071A (zh) | 一种卡西酮人工半抗原、人工抗原及其制备方法和应用 | |
| US2457932A (en) | Salts of tocopheryl phosphoric | |
| US3718680A (en) | Phosphine or phosphite gold complexes of thioethanol and derivatives thereof | |
| CN109438424B (zh) | 利巴韦林半抗原和人工抗原及其制备方法与应用 | |
| HUT72972A (en) | Derivatives of benzoilecgonine, ecgonine and ecgonidine as medicines | |
| Tattrie et al. | THE PREPARATION OF l-α-GLYCERYLPHOSPHORYLCHOLINE FROM LECITHINS | |
| US4812560A (en) | Process for producing 1-β-D-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof | |
| US4192799A (en) | Conjugates formed by reacting a prostaglandin mimic compound with a carrier molecule | |
| Kilgour et al. | Inositol Phosphates: Pinitol 4-Phosphate and (-)-Inositol 3-Phosphate | |
| FI75802C (fi) | Foerfarande foer framstaellning av saosom immunostimulerande aemnen anvaendbara bis- och polydisulfider. | |
| Quin et al. | Stereochemistry of the reaction of oxygen nucleophiles with a phosphinous chloride in the 7-phosphanorbornene series | |
| Lacey et al. | Phospholipid synthesis based on new sequential phosphate and carboxylate ester bond formation steps | |
| CN118409091B (zh) | 一种有机磷农药残留的检测方法 | |
| WO2024022435A1 (zh) | 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法 | |
| Urakami et al. | Selective Reduction of Phosphatides with Lithium Aluminum Hydride. I. Ovolecithin | |
| JPS5838436B2 (ja) | １ ２− ジアルキルケトン−グリセリン −３− ホスフアタイド ノ セイホウ |